Medpace Faces Shareholder Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy MEDP?
Source: Globenewswire
- Lawsuit Background: Medpace Holdings, Inc. is facing a shareholder class action lawsuit alleging that the company issued false and misleading statements regarding its book-to-bill ratio for Q4 2025, failing to disclose the adverse impact of cancellations, which may have led to significant investor losses.
- Investor Rights: Investors who purchased Medpace shares between April 22, 2025, and February 9, 2026, and experienced substantial losses are encouraged to contact Holzer & Holzer law firm to discuss their legal rights, highlighting the firm's commitment to shareholder interests.
- Legal Proceedings: Investors must apply to be appointed lead plaintiff by June 5, 2026, indicating the urgency of the case and its potential impact on Medpace's market reputation and stock price.
- Law Firm Background: Holzer & Holzer, established in 2000, focuses on providing legal support to shareholders and investors, having recovered hundreds of millions for victims of fraud, demonstrating its expertise and success in securities litigation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 496.000
Low
462.00
Averages
569.17
High
660.00
Current: 496.000
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medpace Faces Shareholder Class Action Lawsuit
- Lawsuit Background: Medpace Holdings, Inc. is facing a shareholder class action lawsuit alleging that the company issued false and misleading statements regarding its book-to-bill ratio for Q4 2025, failing to disclose the adverse impact of cancellations, which may have led to significant investor losses.
- Investor Rights: Investors who purchased Medpace shares between April 22, 2025, and February 9, 2026, and experienced substantial losses are encouraged to contact Holzer & Holzer law firm to discuss their legal rights, highlighting the firm's commitment to shareholder interests.
- Legal Proceedings: Investors must apply to be appointed lead plaintiff by June 5, 2026, indicating the urgency of the case and its potential impact on Medpace's market reputation and stock price.
- Law Firm Background: Holzer & Holzer, established in 2000, focuses on providing legal support to shareholders and investors, having recovered hundreds of millions for victims of fraud, demonstrating its expertise and success in securities litigation.
See More
Medpace Holdings Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of securities laws during the period from April 22, 2025, to February 9, 2026, with a deadline for participation set for June 5, 2026.
- False Statements Allegations: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its stock price, which led to investor losses once the truth was revealed, indicating significant misrepresentation in the company's public statements.
- Opportunity for Loss Recovery: Affected shareholders are encouraged to join the lawsuit to seek compensation, with the Schall Law Firm specializing in securities class actions and offering free consultations to help investors understand their rights.
- Lawsuit Status Explanation: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, potentially affecting their rights to claim damages.
See More
Barclays Upgrades IQVIA and Medpace Ratings Amid AI Concerns
- Rating Upgrade: Barclays upgraded IQVIA (IQV) and Medpace (MEDP) from Equal-weight to Overweight, asserting that concerns over AI's impact on contract research organizations (CROs) are overstated, thus presenting attractive entry points for both short-term and long-term investors.
- Stock Performance: Over the past 12 months, Medpace's stock has plummeted by over 46%, while IQVIA has seen a decline of more than 5%, with analysts believing that the sell-off has reset valuations to appealing levels suitable for investor entry.
- Competitor Downgrades: Barclays downgraded Avantor (AVTR) and Pacific Biosciences (PACB) to Underweight, indicating limited upside potential for these companies and suggesting that it may take time for them to catch up as their turnaround stories unfold gradually.
- Market Outlook: While AI is perceived to have a greater impact on CROs, analysts believe fears regarding AI disruption are exaggerated, and both IQVIA and Medpace stocks remain attractive, especially as Medpace's valuation has meaningfully returned to normal levels.
See More
Latest Wall Street Ratings Analysis
- Ormat Technologies Rating: RBC initiates coverage on Ormat Technologies with an Outperform rating and a $130 price target, indicating the geothermal company is well-positioned for market share gains, highlighting its potential in the renewable energy sector.
- Palantir Data Platform: Rosenblatt reiterates Palantir as a Buy, raising the price target from $150 to $200, emphasizing the platform's value amid the Middle East conflict, which suggests strong demand in the data analytics market.
- Varonis Data Security: Wells Fargo rates Varonis as Overweight, asserting that its best-in-class technology is set to capture increasing enterprise demand for data security as AI adoption and SaaS transitions accelerate, positioning the company for significant growth.
- Netflix Future Outlook: Oppenheimer maintains Netflix as Outperform with a $125 target, noting that the absence of the WBD acquisition makes its outlook more predictable, and the resumption of share repurchases will enhance its competitive position in the market.
See More
Bragar Eagel & Squire Investigates Potential Claims Against Medpace
- Financial Performance Analysis: Medpace's Q4 2025 earnings report, released on February 9, 2026, revealed revenues of $708.5 million and GAAP EPS of $4.67, both exceeding market expectations; however, the book-to-bill ratio of 1.04 fell short of the company's forecasts, indicating potential risks to business growth.
- Impact of Cancellations: CEO August Troendle acknowledged that cancellations reached their highest level in over a year, particularly in the metabolic area, although no single large project was responsible, contrasting sharply with previous optimistic projections and potentially raising investor concerns about future performance.
- Stock Price Reaction: Following the earnings disclosure on February 10, 2026, Medpace's shares plummeted approximately 15.9%, with multiple financial outlets identifying the bookings miss as the primary driver of the sell-off, reflecting a significant loss of market confidence in the company's growth prospects.
- Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating whether Medpace has violated federal securities laws, encouraging affected investors to reach out to discuss their legal rights, indicating that the company may face potential legal risks that could impact its reputation and shareholder confidence.
See More
Tom Gardner Discusses AI and Investment Strategies
- Rise of AI Native Companies: Tom Gardner emphasizes that future winners will be AI native companies that fully integrate AI into their culture, enabling them to achieve higher productivity with fewer employees, thus gaining a competitive edge.
- Market Indicator Analysis: Gardner utilizes the Potential Growth Indicator and Market View Tool to guide investment decisions, with the former indicating potential market overvaluation and expected annual returns between 8.5% and 9%, while the latter forecasts closer to 10.5%, reflecting the market's complexity.
- Portfolio Strategy: Gardner stresses that investors should adopt an incremental strategy, focusing on cash inflows into the market to avoid significant losses during market volatility, particularly for those nearing retirement who need to manage their assets cautiously.
- Stock Recommendations for the Next Five Years: He recommends six stocks, including TransMedics, which is expected to triple in value over the next 6-7 years, and Aritzia, which shows strong financial management and growth potential in the U.S. market.
See More
Medpace Faces Shareholder Class Action Lawsuit
- Lawsuit Background: Medpace Holdings, Inc. is facing a shareholder class action lawsuit alleging that the company issued false and misleading statements regarding its book-to-bill ratio for Q4 2025, failing to disclose the adverse impact of cancellations, which may have led to significant investor losses.
- Investor Rights: Investors who purchased Medpace shares between April 22, 2025, and February 9, 2026, and experienced substantial losses are encouraged to contact Holzer & Holzer law firm to discuss their legal rights, highlighting the firm's commitment to shareholder interests.
- Legal Proceedings: Investors must apply to be appointed lead plaintiff by June 5, 2026, indicating the urgency of the case and its potential impact on Medpace's market reputation and stock price.
- Law Firm Background: Holzer & Holzer, established in 2000, focuses on providing legal support to shareholders and investors, having recovered hundreds of millions for victims of fraud, demonstrating its expertise and success in securities litigation.
See More
Medpace Holdings Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of securities laws during the period from April 22, 2025, to February 9, 2026, with a deadline for participation set for June 5, 2026.
- False Statements Allegations: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its stock price, which led to investor losses once the truth was revealed, indicating significant misrepresentation in the company's public statements.
- Opportunity for Loss Recovery: Affected shareholders are encouraged to join the lawsuit to seek compensation, with the Schall Law Firm specializing in securities class actions and offering free consultations to help investors understand their rights.
- Lawsuit Status Explanation: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, potentially affecting their rights to claim damages.
See More
Barclays Upgrades IQVIA and Medpace Ratings Amid AI Concerns
- Rating Upgrade: Barclays upgraded IQVIA (IQV) and Medpace (MEDP) from Equal-weight to Overweight, asserting that concerns over AI's impact on contract research organizations (CROs) are overstated, thus presenting attractive entry points for both short-term and long-term investors.
- Stock Performance: Over the past 12 months, Medpace's stock has plummeted by over 46%, while IQVIA has seen a decline of more than 5%, with analysts believing that the sell-off has reset valuations to appealing levels suitable for investor entry.
- Competitor Downgrades: Barclays downgraded Avantor (AVTR) and Pacific Biosciences (PACB) to Underweight, indicating limited upside potential for these companies and suggesting that it may take time for them to catch up as their turnaround stories unfold gradually.
- Market Outlook: While AI is perceived to have a greater impact on CROs, analysts believe fears regarding AI disruption are exaggerated, and both IQVIA and Medpace stocks remain attractive, especially as Medpace's valuation has meaningfully returned to normal levels.
See More
Latest Wall Street Ratings Analysis
- Ormat Technologies Rating: RBC initiates coverage on Ormat Technologies with an Outperform rating and a $130 price target, indicating the geothermal company is well-positioned for market share gains, highlighting its potential in the renewable energy sector.
- Palantir Data Platform: Rosenblatt reiterates Palantir as a Buy, raising the price target from $150 to $200, emphasizing the platform's value amid the Middle East conflict, which suggests strong demand in the data analytics market.
- Varonis Data Security: Wells Fargo rates Varonis as Overweight, asserting that its best-in-class technology is set to capture increasing enterprise demand for data security as AI adoption and SaaS transitions accelerate, positioning the company for significant growth.
- Netflix Future Outlook: Oppenheimer maintains Netflix as Outperform with a $125 target, noting that the absence of the WBD acquisition makes its outlook more predictable, and the resumption of share repurchases will enhance its competitive position in the market.
See More
Bragar Eagel & Squire Investigates Potential Claims Against Medpace
- Financial Performance Analysis: Medpace's Q4 2025 earnings report, released on February 9, 2026, revealed revenues of $708.5 million and GAAP EPS of $4.67, both exceeding market expectations; however, the book-to-bill ratio of 1.04 fell short of the company's forecasts, indicating potential risks to business growth.
- Impact of Cancellations: CEO August Troendle acknowledged that cancellations reached their highest level in over a year, particularly in the metabolic area, although no single large project was responsible, contrasting sharply with previous optimistic projections and potentially raising investor concerns about future performance.
- Stock Price Reaction: Following the earnings disclosure on February 10, 2026, Medpace's shares plummeted approximately 15.9%, with multiple financial outlets identifying the bookings miss as the primary driver of the sell-off, reflecting a significant loss of market confidence in the company's growth prospects.
- Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating whether Medpace has violated federal securities laws, encouraging affected investors to reach out to discuss their legal rights, indicating that the company may face potential legal risks that could impact its reputation and shareholder confidence.
See More
Tom Gardner Discusses AI and Investment Strategies
- Rise of AI Native Companies: Tom Gardner emphasizes that future winners will be AI native companies that fully integrate AI into their culture, enabling them to achieve higher productivity with fewer employees, thus gaining a competitive edge.
- Market Indicator Analysis: Gardner utilizes the Potential Growth Indicator and Market View Tool to guide investment decisions, with the former indicating potential market overvaluation and expected annual returns between 8.5% and 9%, while the latter forecasts closer to 10.5%, reflecting the market's complexity.
- Portfolio Strategy: Gardner stresses that investors should adopt an incremental strategy, focusing on cash inflows into the market to avoid significant losses during market volatility, particularly for those nearing retirement who need to manage their assets cautiously.
- Stock Recommendations for the Next Five Years: He recommends six stocks, including TransMedics, which is expected to triple in value over the next 6-7 years, and Aritzia, which shows strong financial management and growth potential in the U.S. market.
See More
